Your browser doesn't support javascript.
loading
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.
Januzzi, James L; Zannad, Faiez; Anker, Stefan D; Butler, Javed; Filippatos, Gerasimos; Pocock, Stuart J; Ferreira, João Pedro; Sattar, Naveed; Verma, Subodh; Vedin, Ola; Schnee, Janet; Iwata, Tomoko; Cotton, Dan; Packer, Milton.
Afiliação
  • Januzzi JL; Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Baim Institute for Clinical Research, Boston, Massachusetts, USA. Electronic address: jjanuzzi@partners.org.
  • Zannad F; Université de Lorraine, Inserm Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Centre Hospitalier Régional Universitaire, Nancy, France.
  • Anker SD; Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.
  • Butler J; Department of Medicine, University of Mississippi School of Medicine, Jackson, Mississippi, USA.
  • Filippatos G; National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece.
  • Pocock SJ; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Ferreira JP; Université de Lorraine, Inserm, Centre d'Investigation Clinique Plurithématique 1433, Centre Hospitalier Régional Universitaire de Nancy, French Clinical Research Infrastructure Network, Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.
  • Sattar N; British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
  • Verma S; Division of Cardiac Surgery, St Michael's Hospital and University of Toronto, Toronto, Ontario, Canada.
  • Vedin O; Boehringer Ingelheim AB, Stockholm, Sweden.
  • Schnee J; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.
  • Iwata T; Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
  • Cotton D; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.
  • Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, USA; Imperial College, London, United Kingdom.
J Am Coll Cardiol ; 78(13): 1321-1332, 2021 09 28.
Article em En | MEDLINE | ID: mdl-34556318
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fragmentos de Peptídeos / Compostos Benzidrílicos / Peptídeo Natriurético Encefálico / Insuficiência Cardíaca Sistólica / Inibidores do Transportador 2 de Sódio-Glicose / Glucosídeos Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Coll Cardiol Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fragmentos de Peptídeos / Compostos Benzidrílicos / Peptídeo Natriurético Encefálico / Insuficiência Cardíaca Sistólica / Inibidores do Transportador 2 de Sódio-Glicose / Glucosídeos Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Am Coll Cardiol Ano de publicação: 2021 Tipo de documento: Article País de publicação: Estados Unidos